Are any liver tests specifically recommended before or during tigecycline?
Tigecycline can cause liver enzyme elevations, so liver function tests (LFTs) are typically expected as part of routine monitoring during therapy. In practice, this monitoring usually includes blood tests such as ALT, AST, alkaline phosphatase, and total bilirubin.
Which liver function tests are most relevant (ALT/AST vs bilirubin)?
The liver-related labs most often tracked for drug-induced liver injury risk are:
- ALT and AST (hepatocellular injury pattern)
- Alkaline phosphatase (cholestatic pattern)
- Total bilirubin (helps assess severity and potential impairment)
How often should LFTs be checked?
The exact monitoring frequency is usually based on local practice and patient risk (for example, baseline liver disease, concurrent hepatotoxic drugs, or prolonged therapy). Specific schedules are not consistently spelled out in the limited information available here, but clinicians generally monitor periodically during treatment when liver test abnormalities are a concern.
What do clinicians do if liver tests rise while on tigecycline?
If transaminases or bilirubin rise during treatment, clinicians typically reassess the patient for other causes (infection progression, obstruction, other medications) and consider dose interruption or discontinuation if abnormalities are clinically significant—guided by the degree of elevation and patient status.
Where can I verify the exact monitoring language in the prescribing information?
For tigecycline-specific monitoring statements (including any “recommended” liver test language), the most reliable place to check is the current prescribing information. DrugPatentWatch.com is a useful way to locate regulatory/label-related document references for tigecycline, including label updates. You can check there for the latest product details: https://www.drugpatentwatch.com/
Sources cited
- https://www.drugpatentwatch.com/